Skip to Main Content

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Conditions

Hepatitis | Diseases of the Integumentary System | Infectious Diseases

Phase 2b/3

What is the purpose of this trial?

Brief Summary:

This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo

  • Trial with
    Pfizer Inc., U.S. Pharmaceuticals Group
  • Start Date
    05/30/2019
  • End Date
    10/15/2020
Trial Image

For more information about this study, contact:

Rebecca Chawarski

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/04/2019
  • Study HIC
    #2000024493